Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

AgeX Therapeutics, Inc. (AGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
08/25/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
08/24/2023 SC 13D/A Juvenescence Ltd reports a 78.6% stake in AGEX THERAPEUTICS, INC.
08/14/2023 8-K Quarterly results
Docs: "AgeX Therapeutics Reports Second Quarter 2023 Financial Results ALAMEDA, Calif.——August 14, 2023—AgeX Therapeutics, Inc. , a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023. Balance Sheet Information"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE This Fourth Amendment to Amended and Restated Convertible Promissory Note by and between AgeX Therapeutics Inc., a Delaware corporation and a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of July 21, 2023 . WHEREAS, Borrower and Lender entered into the Amended and Restated Convertible Promissory Note, dated February 9, 2023 ; WHEREAS, Borrower and Lender wish to further amend the Note. NOW, THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower and Lender agree as follows: 1. Definition...",
"SECURED CONVERTIBLE PROMISSORY NOTE This Amendment to Secured Convertible Promissory Note by and between AgeX Therapeutics Inc., a Delaware corporation and a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of July 21, 2023 . WHEREAS, Borrower and Lender entered into the Secured Convertible Promissory Note, dated March 13, 2023 ; WHEREAS, Borrower and Lender wish to further amend the Note. NOW, THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower and Lender agree as follows: 1. Definitions . Capitalized terms used and not defined in th..."
07/21/2023 8-K Quarterly results
07/07/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
06/08/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE"
05/23/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Notice of ...
05/12/2023 8-K Quarterly results
Docs: "AgeX Therapeutics Reports First Quarter 2023 Financial Results ALAMEDA, Calif.——May 12, 2023—AgeX Therapeutics, Inc. , a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023. Balance Sheet Information"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/06/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
03/31/2023 8-K Quarterly results
Docs: "AGEX THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS"
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 SC 13D/A Juvenescence Ltd reports a 78.7% stake in AGEX THERAPEUTICS, INC.
03/15/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "THIS SECURED CONVERTIBLE PROMISSORY NOTE is issued on March 13, 2023 , BY",
"AMENDED AND RESTATED SECURITY AGREEMENT",
"RECITALS",
"Definitions",
"Agreement",
"SECURED CONVERTIBLE FACILITY AGREEMENT This Third Amendment to Secured Convertible Facility Agreement by and between AgeX Therapeutics Inc., a Delaware corporation and Juvenescence Limited, a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB is effective as of March 10, 2023 . WHEREAS, Borrower and Lender, entered into a Secured Convertible Facility Agreement, dated March 30, 2020, as amended by the First Amendment to the Secured Convertible Facility Agreement, dated July 21, 2020 and the Second Amendment to the Secured Convertible Facility Agreement, dated November 12, 2020 ; WHEREAS, the Borrower and Lender wish to amend the Loan Agreement in order to extend the Repayment ..."
02/10/2023 8-K Quarterly results
02/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/27/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
01/27/2023 SC 13D/A Juvenescence Ltd reports a 72.6% stake in AGEX THERAPEUTICS, INC.
12/16/2022 8-K Quarterly results
12/15/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/12/2022 8-K Quarterly results
11/25/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/02/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/25/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/21/2022 8-K Quarterly results
10/05/2022 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
09/16/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy